Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
China Factory Activity Extends Growth in April Despite Global Pressures 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Dollar Holds Near Two-Week High as Fed Hawkish Shift Lifts Yields, Yen Near Intervention Zone 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
EU Warns of Response as U.S. Considers 25% Tariffs on Car Imports 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Tokyo Inflation Slows Despite Energy Pressures and BOJ Policy Outlook 
Markets Stay Strong Despite Oil Shock Concerns as Earnings Drive Investor Confidence 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Asian Stock Markets Rise Amid Wall Street Rally and U.S.-Iran Tensions 
Asian Stocks Slip as Oil Prices Surge and Fed Signals Inflation Risks 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
China Manufacturing PMI Beats Forecasts in April Amid Weak Domestic Demand 
Sanofi, a pharmaceutical company headquartered in Paris, France, announced its acquisition of the American biopharmaceutical firm, Kadmon. It was revealed that the deal is worth $1.9 billion and the French drugmaker made the purchase to further strengthen the growth of its transplant business line.
Sanofi shared the news about its latest acquisition on Wednesday, Sept. 8. The firm confirmed its purchase of Kadmon Holdings just a month after buying Translate BIO, another US-based biotech company for $3.2 billion.
According to Reuters, Sanofi offered to buy Kadmon in cash at $9.50 per share which is equivalent to more or less $1.9 billion. It was mentioned that both of the firms’ boards did not oppose the deal and granted approval for the deal to proceed.
“We are transforming and simplifying our General Medicines business and have shifted our focus on differentiated core assets in key markets,” Sanofi’s executive vice president of general medicines, Olivier Charmeil, said in a press release. “We are thrilled to add Kadmon's Rezurock to our well-established transplant portfolio. Our existing scale, expertise, and relationships in transplant create an ideal platform to achieve the full potential of Rezurock, which will address the significant unmet medical needs of patients with chronic graft-versus-host disease around the world.”
On the other hand, Kadmon’s president and chief executive officer, Harlan Waksal, M.D., said that they were thrilled as Sanofi acknowledged the value of its Rezurock oral medicine for GVHD or chronic graft versus host disease, a crippling immune-mediated condition that affects many blood cancer patients who underwent bone marrow transplants.
He added that by making use of the pharmaceutical company’s global resources and well-known expertise in developing and selling new medicines, Rezurock is now in a better position for international accessibility. Kadmon’s Rezurock is a drug for the treatment of both adults and patients who are 12 years and older. It was approved by the U.S. Federal Drug Administration (FDA) in July.
Finally, with Sanofi’s acquisition of Kadmon, the said medicine will now become the French pharma company’s third drug under its transplant medicine business. This is also its third major purchase in this year alone.
